New data from ASH 2017 raise many questions regarding how these new approaches will fit into the current treatment paradigm for patients with myeloma.
Carol Ann Huff, MD, discusses the clinical impact of the monoclonal antibody daratumumab for the treatment of patients with multiple myeloma, with practical insights for using this agent in your practice.
Shaji Kumar, MD, provides an overview of the latest research on smoldering multiple myeloma, with treatment strategies to consider for your patients.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.